alexa Antidementia Agents are Partially Symptomatic Treatment
ISSN: 2168-975X

Brain Disorders & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Antidementia Agents are Partially Symptomatic Treatment and Partially Disease Modifying Treatment

Koji Hori1*, Kimiko Konishi1,2, Masayuki Tani3, Norihisa Akashi3, Yuka Kitajima4 and Mitsugu Hachisu5
1Department of Psychiatry, Showa University Northern Yokohama Hospital, Kanagawa, Japan
2Tokyo Metropolitan Tobu Medical Center for Persons WITH Developmental/Multiple Disabilities, Tokyo, Japan
3Department of Psychiatry, Showa University Karasuyama Hospital, Tokyo, Japan
4Department of Anesthegiology, School of Medicine Juntendo University, Tokyo, Japan
5Department of Clinical Psychopharmacy, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan
Corresponding Author : Koji Hori
Department of Psychiatry, Showa University
Northern Yokohama Hospital, 35-1 Chigasakichuo
Tsuzukiku, Yokohama-City, Kanagawa, 224-8503, Japan
Tel: +81-45-949-7000
Fax: +81-45-949-7927
E-mail: [email protected]
Received March 14, 2014, Accepted October 18, 2014, Published October 28, 2014
Citation: Hori K, Konishi K, Tani M, Akashi N, Kitajima Y, et al. (2015) Anti-Dementia Agents are Partially Symptomatic Treatment and Partially Disease Modifying Treatment. Brain Disord Ther 4:148. doi:10.4172/2168-975X.1000148
Copyright: © 2015 Hori K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Antidementia agents, i.e., cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) receptor (NMDA-R) antagonist are now considered to be symptomatic treatment. However, ChEIs and NMDA-R antagonist are proven to have neuroprotecting actions against amyloid pathology


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version